Phyogen utilizes bacteriophages to develop targeted therapies for antibiotic-resistant bacterial infections, employing advanced capture technology and human-like model systems to identify and enhance phage efficacy. The company addresses the urgent public health crisis posed by antimicrobial-resistant bacteria, which are projected to cause millions of deaths annually.
Funding
Funding not disclosed
Founders
Product
Problem
Antibiotic-resistant bacterial infections pose a significant and growing threat to global health, with projections estimating millions of deaths annually due to antimicrobial resistance. Traditional broad-spectrum antibiotics are becoming less effective, necessitating the development of new, targeted antimicrobial therapies.
Solution
Phyogen is developing targeted therapies for antibiotic-resistant bacterial infections using bacteriophages, naturally occurring viruses that selectively infect and kill bacteria. The company employs advanced capture technology to isolate and identify phages with high specificity for target bacteria. Phyogen's platform utilizes human-like model systems to mimic the complexity of real infections, enabling the selection and enhancement of phages with improved efficacy. This approach allows Phyogen to develop phage-based therapeutics that can overcome bacterial resistance mechanisms and provide a viable alternative to traditional antibiotics. The company's technology includes directed evolution of new phage variants to accelerate the development of next-generation super phages.
Target Audience
Phyogen's primary target audience includes pharmaceutical companies, healthcare providers, and research institutions focused on developing and implementing novel antimicrobial therapies to combat drug-resistant infections.
Features
- Proprietary phage capture technology for rapid isolation of bacteriophages from natural sources
- Human-like 3D cell culture systems to simulate physiological conditions of infection
- Patented device for directed evolution of phage variants to overcome bacterial resistance
- Genetic profiling and bioclimatic screening to characterize and optimize phage candidates
- Precision phage formulation to create synergistic combinations for clinical trials
- Pre-clinical testing using in-vivo challenge models to validate safety and efficacy